Calidi Biotherapeutics, Inc. CLDI
Health Care · Pharmaceuticals, Biotechnology & Life Sciences · NYSE American · United States · calidibio.com
Clinical-stage biotech pioneering targeted delivery of genetic medicines via its RedTail enveloped oncolytic virus platform; lead candidate CLD-401 (IND-enabling) targets non-small cell lung cancer and head and neck cancer. A 1-for-16 reverse split takes effect 2026-07-31 (ticker unchanged).
Key ratios
ReturnOnAssets TTM -0.98
ReturnOnAssets 2025 -1.1
ReturnOnAssets 2024 -1.12
ReturnOnAssets 2023 -2.87
ReturnOnEquity TTM -3.12
ReturnOnEquity 2025 -7.01